BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20959440)

  • 1. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas.
    Hentic O; Couvelard A; Rebours V; Zappa M; Dokmak S; Hammel P; Maire F; O'Toole D; Lévy P; Sauvanet A; Ruszniewski P
    Endocr Relat Cancer; 2011 Feb; 18(1):51-9. PubMed ID: 20959440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification.
    Yang Z; Tang LH; Klimstra DS
    Am J Surg Pathol; 2011 Jun; 35(6):853-60. PubMed ID: 21566513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.
    McCaffrey JC
    Laryngoscope; 2006 Jan; 116(1):1-11. PubMed ID: 16481800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas.
    Elias D; Sideris L; Liberale G; Ducreux M; Malka D; Lasser P; Duvillard P; Baudin E
    Surgery; 2005 Apr; 137(4):411-6. PubMed ID: 15800487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
    Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
    Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study.
    Elias D; Lasser P; Ducreux M; Duvillard P; Ouellet JF; Dromain C; Schlumberger M; Pocard M; Boige V; Miquel C; Baudin E
    Surgery; 2003 Apr; 133(4):375-82. PubMed ID: 12717354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic analysis of 220 colorectal cancer patients with synchronous liver metastases].
    He YF; Li YH; Zhang DS; Xiang XJ; Xu RH; Pan ZZ; Zhou ZW; Jiang WQ; He YJ; Wan DS
    Ai Zheng; 2006 Sep; 25(9):1153-7. PubMed ID: 16965661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.
    Bettini R; Mantovani W; Boninsegna L; Crippa S; Capelli P; Bassi C; Scarpa A; Pederzoli P; Falconi M
    Dig Liver Dis; 2009 Jan; 41(1):49-55. PubMed ID: 18463008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
    Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
    Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A; Li Y; Forastiere A
    Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer.
    Shaha AR
    Laryngoscope; 2004 Mar; 114(3):393-402. PubMed ID: 15091208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors.
    Hamada A; Yamakado K; Nakatsuka A; Takaki H; Akeboshi M; Takeda K
    J Vasc Interv Radiol; 2004 Aug; 15(8):835-41. PubMed ID: 15297587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies].
    Auernhammer CJ; Jauch KW; Hoffmann JN
    Zentralbl Chir; 2009 Sep; 134(5):410-7. PubMed ID: 19757340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.